Clinical trial
IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma
NCT00349934 · Immutep S.A.S., Industry · Completed
Key facts
| NCT number | NCT00349934 |
|---|---|
| Title | IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma |
| Official title | IMP321 Phase I Study in Metastatic Breast Carcinoma Patients Receiving First-line Paclitaxel |
| Lead sponsor | Immutep S.A.S., Industry |
| Collaborators | Umanis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Biological |
| Interventions | IMP321 |
| Enrollment | 33 |
| Start date | Jul 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Jan 1, 2010 |
| First posted | Jul 10, 2006 |
| Last update posted | Jan 7, 2010 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: